AREV Life Sciences Global Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for AREV Life Sciences Global.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	54.4%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

Jan 02

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat AREV Life Sciences Global onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

CNSX:AREV - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CAD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2022	0	-1	0	0	N/A
6/30/2022	0	-1	0	0	N/A
3/31/2022	0	-1	-1	-1	N/A
12/31/2021	0	-1	-1	-1	N/A
9/30/2021	0	-2	-1	-1	N/A
6/30/2021	0	-2	-1	-1	N/A
3/31/2021	0	-2	-1	-1	N/A
12/31/2020	0	-1	0	0	N/A
9/30/2020	0	-1	0	0	N/A
6/30/2020	0	-1	0	0	N/A
3/31/2020	0	-2	0	0	N/A
12/31/2019	0	-3	0	0	N/A
9/30/2019	0	-10	-1	-1	N/A
6/30/2019	0	-10	-1	-1	N/A
3/31/2019	0	-9	-1	-1	N/A
12/31/2018	N/A	-8	-1	-1	N/A
9/30/2018	N/A	-2	-1	-1	N/A
6/30/2018	N/A	-1	-1	-1	N/A
3/31/2018	N/A	-1	-1	-1	N/A
12/31/2017	N/A	-1	-1	0	N/A
9/30/2017	N/A	-1	0	0	N/A
6/30/2017	N/A	0	0	0	N/A
3/31/2017	N/A	0	0	0	N/A
12/31/2016	N/A	0	0	0	N/A
9/30/2016	N/A	0	0	0	N/A
6/30/2016	N/A	0	N/A	0	N/A
3/31/2016	N/A	0	N/A	0	N/A
12/31/2015	N/A	0	N/A	0	N/A
9/30/2015	N/A	0	N/A	0	N/A
6/30/2015	N/A	0	N/A	0	N/A
3/31/2015	N/A	0	N/A	0	N/A
12/31/2014	N/A	0	N/A	0	N/A
9/30/2014	0	0	N/A	0	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	N/A	0	N/A	0	N/A
12/31/2013	N/A	0	N/A	0	N/A
9/30/2013	0	0	N/A	0	N/A
6/30/2013	0	0	N/A	0	N/A
3/31/2013	N/A	0	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if AREV's forecast earnings growth is above the savings rate (1.9%).

Winst versus markt: Insufficient data to determine if AREV's earnings are forecast to grow faster than the Canadian market

Hoge groeiwinsten: Insufficient data to determine if AREV's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if AREV's revenue is forecast to grow faster than the Canadian market.

Hoge groei-inkomsten: Insufficient data to determine if AREV's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if AREV's Return on Equity is forecast to be high in 3 years time

AREV Life Sciences Global Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024

No independent directors

No independent directors

No independent directors

AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from Board

No independent directors

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)

Chairman & CEO recently bought CA$59k worth of stock

No independent directors

AREV Life Sciences Global Corp. Announces Management Changes

Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)

AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory Board

Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)

No independent directors

AREV Life Sciences Global Corporation Appoints Brian V. Elliott to its Board of Directors

AREV Life Sciences Global Corp. Appoints Kevin Phelps as Chief Operating Officer

AREV Life Sciences Global Corp. Appoints Douglas Sorocco to Its Scientific Advisory Committee

AREV Life Sciences Settles Pending Litigation with Harvey

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million.

Chairman & CEO exercised options to buy CA$200k worth of stock.

Chairman & CEO recently sold CA$125k worth of stock

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)

AREV NanoTec Brands Inc. Expands Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based Drugs

AREV NanoTec Brands Inc. announced that it has received CAD 0.67 million in funding

Arev Nanotec Brands Inc. Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate Development

AREV NanoTec Brands Inc. Announces Addition of Kevin J. Phelps to its Board of Directors

AREV NanoTec Brands Inc. Appoints Dr. Jay Noller to its Scientific Advisory Board

AREV’s Nanotech Initiates Early-Stage Antiviral Photochemistry Derivation Discovery Program for Pandemic Viral Pathogens

New 90-day high: CA$0.42

AREV Appoints Dr. Roscoe Moore to Join the Advisory Board

AREV NanoTec Brands Inc. Corporate Update on Latest Innovation

AREV NanoTec Brands Inc. Appoints Dr. Uma V. A. Dhanabalan as Advisory Board

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.725 million in funding

AREV NanoTec Brands Inc. announced that it has received CAD 0.1 million in funding from Chiron Partners LLC

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

New 90-day high: CA$0.22

Chairman & CEO recently sold CA$261k worth of stock

AREV NanoTec Brands Inc. Receives Its First Trial Run of Its Naturvac Immune Boost

AREV NanoTec Brands Inc. Appoints Don Shaxon to the Position of VP Marketing

First half earnings released

AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California.

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.16 million in funding

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven